Dr. Hidalgo Medina on MSI and Germline Testing in Pancreatic Cancer

Video

In Partnership With:

Manuel Hidalgo Medina, MD, PhD, discusses microsatellite instability and germline testing patients with pancreatic cancer.

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses microsatellite instability (MSI) and germline testing patients with pancreatic cancer.

Patients should be tested for MSI upon diagnosis, explains Hidalgo Medina. There are indications that other molecular subgroups, such as NTRK fusions, get clear benefit from certain treatments, illustrating that all patients should receive germline testing upon diagnosis, as well. Knowing if patients harbor select biomarkers or mutations help physicians determine best standard of care or what clinical trials are most suited for patients.

Repeat MSI and germline testing, according to Hidalgo Medina, is not required. However, upon progression, it may be beneficial to rebiopsy the patient and sequence again to offer more opportunities for clinical trials, concludes Hidalgo Medina.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS